Lymphocytic Leukemia, Acute News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Venetoclax for Older Patients With AML? 'Remarkable' Response - Medscape



Medscape
 
Venetoclax for Older Patients With AML? 'Remarkable' Response 
Medscape
Less than 30% of patients achieve a clinical response, median survival is less than 1 year, and neither drug is curative, they point out. This phase 1b study provides hope for patients who need one. While venetoclax has changed the treatment landscape ...

 


Monitoring for AML Remissions: Are We Measuring Properly? - Curetoday.com



Curetoday.com
 
Monitoring for AML Remissions: Are We Measuring Properly? 
Curetoday.com
The monitoring of MRD is currently used frequently in myeloma and chronic lymphocytic leukemia, and is beginning to show progress in acute lymphoblastic leukemia. Stone is hopeful that one day, MRD will play as key a role in AML as it does with other ...

and more » 


Benefit will help Williston toddler with leukemia - Williston Daily Herald



Williston Daily Herald
 
Benefit will help Williston toddler with leukemia 
Williston Daily Herald
A benefit dinner, auction and concert Jan. 27 at Midway Crossing will help 2-year-old Aryan Williams, who was diagnosed with acute lymphoblastic leukemia. Submitted. Facebook · Twitter · Email; Print; Save. Aryan Williams was always a happy, cheerful ...

 


Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense - Investor's Business Daily



Investor's Business Daily
 
Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense 
Investor's Business Daily
After, Juno will look at other possible uses, including other leukemias and lymphomas, Leerink analyst Michael Schmidt said in a note to clients. In total, he estimates $1.7 billion in U.S. peak sales in 2025, assuming a best-case scenario. Schmidt ...
Digging Into The Data: Juno Therapeutics Inc. (NASDAQ:JUNO) TopChronicle
Juno stock jumps as reports suggest Celgene wants a buyout FierceBiotech
Trader's Buzzers: TripAdvisor Inc. (NASDAQ:TRIP), Juno Therapeutics Inc. (NASDAQ:JUNO) The Oracle Examiner
Warrior Trading News (press release)  -Frisco Fastball  -Wall Street Journal  -Zacks Investment Research 
all 167 news articles » 


Finding God as a St. Jude child with cancer - The Commercial Appeal



The Commercial Appeal
 
Finding God as a St. Jude child with cancer 
The Commercial Appeal
On Oct. 11, 1994, my life changed forever. In for a regular pediatric check-up, my pediatrician at the time noticed alarmingly high white-blood cell levels. He referred my parents to St. Jude Children's Research Hospital. On that day I was diagnosed ...

 


FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma - Lymphoma News Today



Lymphoma News Today
 
FDA Promises Rapid Review of Kymriah for Diffuse Large B-cell Lymphoma 
Lymphoma News Today
Kymriah became the first commercially available CAR T-cell therapy when it was approved in the U.S. in August 2017 for the treatment of relapsed or treatment-resistant B-cell acute lymphoblastic leukemia (ALL) in children and adolescents. Meanwhile ...
Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA Zacks.com

all 2 news articles » 


Complication sends young leukemia patient back to local hospital - KWTX



KWTX
 
Complication sends young leukemia patient back to local hospital 
KWTX
Hours after she started the final treatment Tuesday, she developed a fever and her parents took her to the emergency room. She was later admitted to McLane Children's Hospital. "Although the doctor thinks she has viral meningitis (which is what we want ...

 


Gilead/Kite team up with Pfizer for CAR-T-mAb combination - FierceBiotech



FierceBiotech
 
Gilead/Kite team up with Pfizer for CAR-T-mAb combination 
FierceBiotech
The newly combined company is lining up to battle Novartis, which has its CAR-T Kymriah (tisagenlecleucel) approved in the U.S. for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Yesterday, the therapy was ...

and more » 


NVS' Kymriah To Face FDA Again, AEZS Teams Up With SBBP, A ... - Nasdaq



NVS' Kymriah To Face FDA Again, AEZS Teams Up With SBBP, A ... 
Nasdaq
(RTTNews.com) - Today's Daily Dose brings you news about Aeterna's alliance with Strongbridge; a new study about CellMax-CRC Colorectal Cancer Screening test and Novartis' Kymriah getting priority review from the FDA for a second indication. Read on ...

and more » 


JUNO Flies On Takeover Rumor, PRTO For Long Haul, SUPN Gaining Strength - Markets Insider



JUNO Flies On Takeover Rumor, PRTO For Long Haul, SUPN Gaining Strength 
Markets Insider
Juno's lead CAR-T therapy candidate is JCAR017, and it is under phase I/II testing in Diffuse large B-cell lymphoma, Chronic lymphocytic leukemia and acute lymphocytic leukemia. Juno has a ten-year collaboration in place with Celgene that was inked in ...